ResMed

NYSE: RMD
New York Stock Exchange
Healthcare Medical Instruments & Supplies
Global Rank
#794
Country Rank
#313
Market Cap
32.65 B
Price
228.25
Change (%)
0.52%
Volume
1.07 M

ResMed's latest marketcap:

32.65 B

As of 09/17/2026, ResMed's market capitalization has reached $32.65 B. According to our data, ResMed is the 794th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 32.65 B
Revenue (ttm) 5.65 B
Net Income (ttm) 1.52 B
Shares Out 143.06 M
EPS (ttm) 10.43
Forward PE 18.90
Ex-Dividend Date 08/20/2026
Earnings Date 10/29/2026
Market Cap Chart
Data Updated: 09/17/2026

ResMed's yearly market capitalization.

ResMed has seen its market value grow from $665.7 M to $32.65 B since 1998, representing a total increase of 4,805.21% and an annual compound growth rate (CAGR) of 15.08%.
Date Market Cap($) Change (%) Global Rank
09/17/2026 $32.65 B -9.26% 794
12/31/2025 $35.16 B 4.73% 567
12/31/2024 $33.57 B 32.68% 576
12/29/2023 $25.3 B -17.01% 718
12/30/2022 $30.49 B -19.68% 553
12/31/2021 $37.96 B 23.23% 519
12/31/2020 $30.8 B 38.24% 571
12/31/2019 $22.28 B 37.32% 639
12/31/2018 $16.23 B 35.02% 705
12/29/2017 $12.02 B 37.39% 1085

Company Profile

About ResMed Inc.

ResMed Inc. is a global leader in developing, manufacturing, and distributing medical devices and cloud-based software solutions for healthcare markets. Founded in 1989 and headquartered in San Diego, California, the company serves sleep clinics, home healthcare providers, and hospitals through a network of distributors and direct sales.

Business Segments

  • Sleep and Respiratory Care: Focuses on innovative solutions for respiratory disorders, including sleep apnea.
  • Software as a Service (SaaS): Provides cloud-based healthcare management and monitoring tools.

Key Products & Solutions

  • Diagnostic Devices: ApneaLink Air (portable diagnostic tool) and NightOwl (cloud-connected diagnostic device).
  • Remote Monitoring: AirView (cloud-based patient monitoring) and myAir (personalized therapy management app).
  • Compliance Solutions: U-Sleep (streamlines sleep programs) and Propeller (connectivity modules).
  • Out-of-Hospital Software: Brightree (HME management), MatrixCare (senior living solutions), HEALTHCAREfirst (home health EHR), and MEDIFOX DAN (specialized software).

Market Reach

ResMed serves a diverse clientele, including sleep clinics, home healthcare dealers, and hospitals, ensuring better respiratory care and streamlined healthcare operations worldwide.

Frequently Asked Questions

  • What is ResMed's (RMD) current market cap?
    As of 09/17/2026, ResMed (including the parent company, if applicable) has an estimated market capitalization of $32.65 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
  • ResMed global market capitalization ranking is approximately 794 as of 09/17/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

MarketCapWatch.com ranks all listed companies worldwide, providing unique insights into market capitalization across industries. As one of the most comprehensive ranking platforms, it covers companies of all sizes and sectors.

Research Tools

Copyright © 2026. All rights reserved

Important Disclaimer: All content provided on this website, including hyperlinked pages, related applications, forums, blogs, social media accounts, and other platforms ("the Site"), is for general informational purposes only and sourced from third-party providers. We make no guarantees regarding the accuracy, completeness, or timeliness of the content.

None of the information presented constitutes financial, legal, or professional advice. Users should conduct their own research, evaluation, and verification before making any decisions. Investing and trading carry significant risks that may lead to substantial losses. Therefore, we strongly recommend consulting a qualified financial advisor before taking any action.